%0 Journal Article
%T First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age
%A Petrillo, Angelica
%A Pappalardo, Annalisa
%A Calabrese, Filomena
%A Tirino, Giuseppe
%A Pompella, Luca
%A Ventriglia, Jole
%A Laterza, Maria Maddalena
%A Caterino, Marianna
%A Sforza, Vincenzo
%A Iranzo, Vega
%A Biglietto, Maria
%A Orditura, Michele
%A Ciardiello, Fortunato
%A Conzo, Giovanni
%A Molino, Carlo
%A De Vita, Ferdinando
%J Journal of Gastrointestinal Oncology
%D 2019
%B 2019
%9 
%! First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age
%K 
%X Background: Nab-paclitaxel plus gemcitabine represents one of the standard regimens for first line treatment of metastatic pancreatic cancer (mPC). Few data are available on nab-paclitaxel plus gemcitabine in geriatric population. Our study aims to show whether this schedule can be feasible in the elderly as first-line treatment for mPC.   Methods: We retrospectively analyzed the data of 64 mPC patients (≥65 years old) treated according to the MPACT schedule.   Results: Median age was 69.5 years (range, 65–80 years); after a median of 5 cycles administered (range, 1–12), the most common adverse events (AEs) were grade 2 alopecia (46.9%), anemia (17.2%) and hypertransaminasemia (10.9%); all grades neutropenia occurred in 20.3% of pts. Global incidence of grade 3 and 4 toxicities were 26.5% and 0%, respectively, and no patients stopped treatment due to unacceptable toxicity. Stable disease (SD) was observed in 31.2% of patients, with a disease control rate (DCR) and overall response rate of 57.8% and 26.6%, respectively. After a median follow-up of 18 months, median progression free survival (PFS) was 8 months (95% CI: 6.3–9.6) and median OS was 12.0 months (95% CI: 8.4–15.6). The univariate analysis for overall survival (OS) showed that only ECOG performance status was an independent prognostic factor for survival.   Conclusions: Nab-paclitaxel plus gemcitabine schedule is feasible and effective in the “daily clinical practice” geriatric population.
%U https://jgo.amegroups.org/article/view/29758
%V 10
%N 5
%P 910-917
%@ 2219-679X